Long-term narrowband ultraviolet B (NB-UVB) therapy may decrease risk for cardiovascular and cerebrovascular events in patients with vitiligo, according to study data published in the Journal of the European Academy of Dermatology and Venereology.

Investigators extracted data from the Korean National Health Insurance claims database for the years 2007 through 2017. Patients aged ≥40 years with a clinical diagnosis of vitiligo were eligible for study inclusion.